Detalles de la búsqueda
1.
Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial.
Brain
; 146(2): 461-474, 2023 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36256599
2.
Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study.
Mol Genet Metab
; 138(2): 106963, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36481125
3.
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.
Am J Hematol
; 96(9): 1156-1165, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34161616
4.
Impact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1.
Mol Genet Metab
; 129(2): 117-124, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31924461
5.
Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.
Blood
; 129(17): 2375-2383, 2017 04 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-28167660
6.
Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.
Am J Hematol
; 94(1): 29-38, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30264864
7.
A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration.
Blood Cells Mol Dis
; 68: 185-191, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28126395
8.
Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial.
Mol Genet Metab
; 123(3): 347-356, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29358012
9.
Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
Am J Hematol
; 92(11): 1170-1176, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28762527
10.
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial.
J Parkinsons Dis
; 12(2): 557-570, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34897099
11.
Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials.
JIMD Rep
; 57(1): 76-84, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33473343
12.
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 10(1): 86-98, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32851809
13.
Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1.
Orphanet J Rare Dis
; 14(1): 128, 2019 06 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31174576
14.
The effect of administering erythropoiesis-stimulating proteins in patients with chronic heart failure: results from a retrospective study.
Congest Heart Fail
; 12(6): 297-301, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-17170581
15.
Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial.
Mol Genet Metab Rep
; 9: 25-28, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27722092
16.
Is bridging to transplantation with a left ventricular assist device a risk factor for transplant coronary artery disease?
J Heart Lung Transplant
; 24(6): 703-7, 2005 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15949730
Resultados
1 -
16
de 16
1
Próxima >
>>